305 related articles for article (PubMed ID: 21309961)
21. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
Burns A; Spiegel R; Quarg P
Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
[TBL] [Abstract][Full Text] [Related]
22. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease.
Grossberg GT; Sadowsky C; Olin JT
Int J Clin Pract; 2010 Apr; 64(5):651-60. PubMed ID: 20102418
[TBL] [Abstract][Full Text] [Related]
23. Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.
Han HJ; Kim BC; Lee JY; Ryu SH; Na HR; Yoon SJ; Park HY; Shin JH; Cho SJ; Yi HA; Choi MS; Heo JH; Park KW; Kim KK; Choi SH
Dement Geriatr Cogn Disord; 2012; 34(3-4):167-73. PubMed ID: 23051684
[TBL] [Abstract][Full Text] [Related]
24. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
Kulkantrakorn K; Tanyakitpisal P; Towanabut S; Dejthevaporn C; Rangseekajee P; Pongpakdee S; Laptikultham S; Rodprasert K; Setthawatcharawanich S; Thinkhamrop B
Psychogeriatrics; 2013 Mar; 13(1):1-8. PubMed ID: 23551405
[TBL] [Abstract][Full Text] [Related]
25. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.
Blesa R; Ballard C; Orgogozo JM; Lane R; Thomas SK
Neurology; 2007 Jul; 69(4 Suppl 1):S23-8. PubMed ID: 17646620
[TBL] [Abstract][Full Text] [Related]
26. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease.
Grossberg G; Cummings J; Frölich L; Bellelli G; Molinuevo JL; Krahnke T; Strohmaier C
Am J Alzheimers Dis Other Demen; 2013 Sep; 28(6):583-91. PubMed ID: 23982674
[TBL] [Abstract][Full Text] [Related]
28. Rivastigmine for Alzheimer's disease.
Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
[TBL] [Abstract][Full Text] [Related]
29. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
[TBL] [Abstract][Full Text] [Related]
30. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.
Farlow MR; Grossberg GT; Sadowsky CH; Meng X; Somogyi M
CNS Neurosci Ther; 2013 Oct; 19(10):745-52. PubMed ID: 23924050
[TBL] [Abstract][Full Text] [Related]
31. A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease.
Farlow MR; Grossberg GT; Sadowsky CH; Meng X; Velting DM
Alzheimer Dis Assoc Disord; 2015; 29(2):110-6. PubMed ID: 25437301
[TBL] [Abstract][Full Text] [Related]
32. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
Darreh-Shori T; Jelic V
Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
[TBL] [Abstract][Full Text] [Related]
33. Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.
Grossberg GT; Schmitt FA; Meng X; Tekin S; Olin J
Am J Alzheimers Dis Other Demen; 2010 Dec; 25(8):627-33. PubMed ID: 21131668
[TBL] [Abstract][Full Text] [Related]
34. Rivastigmine for Alzheimer's disease.
Birks JS; Grimley Evans J
Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
[TBL] [Abstract][Full Text] [Related]
35. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.
Barone P; Burn DJ; van Laar T; Hsu C; Poewe W; Lane RM
Mov Disord; 2008 Aug; 23(11):1532-40. PubMed ID: 18581467
[TBL] [Abstract][Full Text] [Related]
36. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease.
Winblad B; Kawata AK; Beusterien KM; Thomas SK; Wimo A; Lane R; Fillit H; Blesa R
Int J Geriatr Psychiatry; 2007 May; 22(5):485-91. PubMed ID: 17407176
[TBL] [Abstract][Full Text] [Related]
37. Rivastigmine exposure provided by a transdermal patch versus capsules.
Mercier F; Lefèvre G; Huang HL; Schmidli H; Amzal B; Appel-Dingemanse S
Curr Med Res Opin; 2007 Dec; 23(12):3199-204. PubMed ID: 18001519
[TBL] [Abstract][Full Text] [Related]
38. Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).
Zhang ZX; Hong Z; Wang YP; He L; Wang N; Zhao ZX; Zhao G; Shang L; Weisskopf M; Callegari F; Strohmaier C
CNS Neurosci Ther; 2016 Jun; 22(6):488-96. PubMed ID: 27012596
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
Lefèvre G; Sedek G; Jhee SS; Leibowitz MT; Huang HL; Enz A; Maton S; Ereshefsky L; Pommier F; Schmidli H; Appel-Dingemanse S
Clin Pharmacol Ther; 2008 Jan; 83(1):106-14. PubMed ID: 17522596
[TBL] [Abstract][Full Text] [Related]
40. Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease.
Grossberg G; Meng X; Olin JT
Am J Alzheimers Dis Other Demen; 2011 Feb; 26(1):65-71. PubMed ID: 21282280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
